I am also anticipating responses somewhere around 30% for the preliminary analysis. DVAX's BORR at 21.4% is probably the most promising at the moment for actual nonresponders (to anti-pd-1) with advanced melanoma. We'll see what tomorrow brings.
The phase 1 TNBC study was also only designed to detect immunological responses after a single cycle of treatment on TAVO. The fact that 2/2 patients who went straight on to anti-pd-1 treatment immediately after TAVO responded is very, very intriguing given that only 5% of TNBC patients ever respond to anti-pd-1 therapy.
Market Data 
Markets 
AI
